Pahl, Jennifer
Prokopiou, Prokopis C.
Bueichekú, Elisenda
Schultz, Aaron P.
Papp, Kathryn V.
Farrell, Michelle E.
Rentz, Dorene M.
Sperling, Reisa A.
Johnson, Keith A.
Jacobs, Heidi I.L.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (269953372/GRK2150)
National Institutes of Health (R21AG081681, P01AG036694, P01AG036694, R01AG062559)
Article History
Received: 2 February 2024
Accepted: 22 May 2024
First Online: 31 May 2024
Declarations
:
: All study procedures were approved by the Partners Healthcare Institutional Review Board in accordance with the Belmont Report, and in full compliance with all applicable federal, state, and local laws and regulations. All participants provided written informed consent.
: Not applicable.
: A.P.S. has been a paid consultant for Janssen Pharmaceuticals and Biogen. K.V.P. is funded by NIA grant K23 AG053422-01 and the Alzheimer’s Association and has served as a paid consultant for Biogen. R.A.S. has served as paid consultant for AC Immune, Alector, Acumen, Bristol Myers Squibb, Genentech, NervGen, Oligomerix, Prothena, Renew, Vigil Neuroscience, Ionis, and Vaxxinity. She receives research support from Eisai and Eli Lilly as part of public-private partnership clinical trials, and also receives research support from the following grants: P01 AG036694, U24 AG057437, R01 AG063689, R01 AG054029, R01 AG053798, GHR Foundation, National Institute on Aging, Fidelity Biosciences, and the Alzheimer’s Association. K.A.J. has served as paid consultant for Janssen, Genzyme, Novartis, Biogen, Roche, and AC Immune. He is a site co- investigator for Lilly/Avid and Janssen, and receives research support for clinical trials from Eisai, Lilly and Cerveau. He received funding from NIH grants R01 EB014894, R21 AG038994, R01 AG026484, R01 AG034556, P50 AG00513421, U19 AG10483, P01 AG036694, R13 AG042201174210, R01 AG027435, and R01 AG037497 and the Alzheimer’s Association grant ZEN-10-174210. These relationships are not related to the content of the manuscript. All other authors declare no competing interests.